Short course radiation

RADIATION3 trials

Sponsors

Massachusetts General Hospital, University of Iowa, University of Vermont Medical Center

Conditions

Cutaneous Squamous Cell Carcinoma (CSCC)Pancreatic CancerRectal Neoplasm MalignantRectal Neoplasms

Phase 1

A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers

TerminatedNCT04926324

University of IowaRectal Neoplasm Malignant, Rectal Neoplasms

Start: 2022-07-07End: 2025-11-24Updated: 2026-06-29

Phase 2

FOLFIRINOX + RT for Pancreatic Cancer

CompletedNCT01591733

Massachusetts General HospitalPancreatic Cancer

Start: 2012-08-02End: 2021-04-15Updated: 2026-09-04

MOHs Surgery and Short-Course Radiation Therapy With Structured Follow-Up for Head & Neck Squamous Cell Skin Cancer

RecruitingNCT06998342

University of Vermont Medical CenterCutaneous Squamous Cell Carcinoma (CSCC)

Start: 2025-06-04End: 2031-05-01Target: 24Updated: 2026-05-26

Related Papers

Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic Cancer

Clinical Cancer Research2023-02-0743 citations

Abstract C043: Addition of losartan to FOLFORINOX and chemoradiation downregulates pro-invasion and immunosuppression-associated genes in locally advanced pancreatic cancer

Cancer Research2022-11-152 citations

1463 Addition of losartan to FOLFORINOX and chemoradiation downregulates pro-invasion and immunosuppression associated genes in locally advanced pancreatic cancer

Regular and Young Investigator Award Abstracts2022-11-011 citations

Population pharmacokinetics and exposure–response of anti‐programmed cell death protein‐1 monoclonal antibody dostarlimab in advanced solid tumours

British Journal of Clinical Pharmacology2022-03-3125 citations

Local and systemic recurrence following total neoadjuvant therapy (TNT) and resection for borderline resectable and locally advanced pancreatic adenocarcinoma: Long-term follow up from two phase II studies.

Journal of Clinical Oncology2021-05-20

Dose intensity of neoadjuvant FOLFIRINOX (FFX) in borderline and locally advanced pancreatic cancer (LAPC): A comparison to the adjuvant benchmark.

Journal of Clinical Oncology2019-01-293 citations

Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma

JAMA Oncology2018-05-03531 citations

FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer (BRPC): Toxicity, R0 resection, and interim survival data from a prospective phase II study.

Journal of Clinical Oncology2017-05-201 citations

FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer: Preliminary toxicity and R0 resection rates from a prospective phase II study.

Journal of Clinical Oncology2017-02-011 citations